DURHAM, N.C. (PRWEB) MAY 29, 2018 – Nocturnal Product Development, LLC (Research Triangle Park, NC) has entered into a strategic global partnership with TechWald Holding SpA (Turin, Italy and Tel-Aviv, Israel) to evaluate, fund, and develop innovative medical technologies.

“We are excited to announce this partnership with TechWald Holding as it enhances our service capabilities in the US and expands our footprint into Europe and Israel. We believe that a prearranged partnership with a global source of funds completes our development lifecycle offerings to our clients. With an international funding option, this partnership grows the RTP ecosystem, provides access to physicians in Europe and Israel, and will result in getting products to the market much quicker.” says Terry Ransbury, President of Nocturnal.

“The partnership with Nocturnal Product Development is contributing a strategic asset to TechWald Holding network of expertise in scouting and assessing innovative medical technology, and in enhancing the development capabilities of its invested companies, with the ultimate goal of retiring innovation development risks and increasing financial returns for our investors” says Alessandro Piga, Managing Director of TechWald Holding.

Nocturnal Product Development, LLC is a medical device development firm located near Research Triangle Park, Durham, North Carolina. The company specializes in multi-disciplinary technology product development with expertise in: electrical design, mechanical design, embedded software, optics, IOT, wireless, cloud-based applications, project management, and clinical & regulatory strategy.

TechWald Holding S.p.A – TWH – is an international participation holding company located in Italy and Israel and investing in healthcare innovation with a key strategic focus on the MedTech industry and on medical technologies and solutions which can demonstrate strong benefit and value for healthcare community and reward investors with a sound and ethical profit. TWH approach is to maximize the risk-adjusted return on investments in technologies whose innovation is more effective for patients and physicians, more efficient for healthcare providers and more sustainable for healthcare payers.